InnoCare Announces Approval of the Next-Generation TRK Inhibitor Zurletrectinib in China
BEIJING, Dec. 11, 2025 (GLOBE NEWSWIRE) — InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company, announced today that its next-generation TRK inhibitor, zurletrectinib (ICP-723), has received approval from the China National Medical
(Financial Post, 2025-12-11T11:05:10Z)